Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib/II study of TTI-622 in a combination with anti-PD-1 in relapsed/refractory diffuse large B-cell lymphoma patients

Next Previous
Trial Profile

Phase Ib/II study of TTI-622 in a combination with anti-PD-1 in relapsed/refractory diffuse large B-cell lymphoma patients

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 05 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maplirpacept (Primary) ; Programmed cell death-1 ligand-1 inhibitors
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 05 May 2021 New trial record
  • 28 Apr 2021 According to a Trillium Therapeutics media release, the company plans to initiate this study in 4Q 2021 to 1H 2022.
  • 28 Apr 2021 According to a Trillium Therapeutics media release, this is an investigator-sponsored trial at Mayo Clinic

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top